GT BIOPHARMA INC (GTBP) Stock Price & Overview
NASDAQ:GTBP • US36254L3087
The current stock price of GTBP is 0.425 USD. Today GTBP is down by -3.41%. In the past month the price decreased by -9.77%. In the past year, price decreased by -83.4%.
GTBP Key Statistics
- Market Cap
- 11.326M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.66
- Dividend Yield
- N/A
GTBP Stock Performance
GTBP Stock Chart
GTBP Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GTBP. When comparing the yearly performance of all stocks, GTBP is a bad performer in the overall market: 96.49% of all stocks are doing better.
GTBP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GTBP. The financial health of GTBP is average, but there are quite some concerns on its profitability.
GTBP Earnings
GTBP Forecast & Estimates
7 analysts have analysed GTBP and the average price target is 8.16 USD. This implies a price increase of 1820% is expected in the next year compared to the current price of 0.425.
GTBP Groups
Sector & Classification
GTBP Financial Highlights
Over the last trailing twelve months GTBP reported a non-GAAP Earnings per Share(EPS) of -1.66.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -215.85% | ||
| ROE | -310.9% | ||
| Debt/Equity | 0 |
GTBP Ownership
GTBP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.19 | 398.492B | ||
| AMGN | AMGEN INC | 16.11 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.43 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.66 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.52 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.5 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.84 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 339.75 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GTBP
Company Profile
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Company Info
IPO: 2013-10-22
GT BIOPHARMA INC
505 Montgomery Street, 10Th Floor
San Francisco CALIFORNIA 90212 US
CEO: Anthony J. Cataldo
Employees: 1
Phone: 18003049888
GT BIOPHARMA INC / GTBP FAQ
What does GTBP do?
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
What is the stock price of GT BIOPHARMA INC today?
The current stock price of GTBP is 0.425 USD. The price decreased by -3.41% in the last trading session.
Does GT BIOPHARMA INC pay dividends?
GTBP does not pay a dividend.
How is the ChartMill rating for GT BIOPHARMA INC?
GTBP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for GTBP stock?
7 analysts have analysed GTBP and the average price target is 8.16 USD. This implies a price increase of 1820% is expected in the next year compared to the current price of 0.425.
What is GT BIOPHARMA INC worth?
GT BIOPHARMA INC (GTBP) has a market capitalization of 11.33M USD. This makes GTBP a Nano Cap stock.
Can you provide the short interest for GTBP stock?
The outstanding short interest for GT BIOPHARMA INC (GTBP) is 10.14% of its float.